WO-12

N/A

Report date: 2025/01/26 17:07:40

Base Information

Drug NameWO-12
Drug Alias Namegenetically modified virus-based immunotherapy (University of Pittsburg)Oncolytic Vaccinia Virus Therapy Expressing TRIF and HPGD (Western Oncolytics)genetically modified virus-based immunotherapy (Western Oncolytics)WO-12
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesWestern Oncolytics LtdPfizer Inc
Inactive CompaniesUniversity Of Pittsburgh
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A